The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
More than 200 drivers a day were caught using their mobile phones illegally in the wake of a major crackdown on the practice.
Tougher sentences will be handed out to perpetrators of domestic violence against children under plans being set out by the Conservatives.
Two people have been arrested after a car crashed into pedestrians in Marbella.